medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2013, Número 2

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2013; 11 (2)


Reacción por drogas con eosinofilia: Síndrome DRESS, un gran simulador

Osuna OJ, Toledo BME, Valencia HA, Ramírez CE, Mena CC

Idioma: Español
Referencias bibliográficas: 25
Paginas: 142-147
Archivo PDF: 136.38 Kb.


RESUMEN

La reacción por drogas con eosinofilia y síntomas sistémicos (DRESS, por sus siglas en inglés) es un síndrome raro y grave cuya patogénesis no ha sido del todo esclarecida y conlleva una elevada tasa de mortalidad (10-20%). Se ha observado más comúnmente asociada con el uso de antibióticos, antiepilépticos y antihipertensivos. Los síntomas y signos principales incluyen fiebre, casi siempre elevada y persistente; erupción morbiliforme; eosinofilia en más de 90%; y compromiso multiorgánico, particularmente hepático. El diagnóstico se basa en los hallazgos clínicos y de laboratorio, y el fundamento terapéutico es la suspensión del agente causal aunada a la administración de esteroides, con inmunoglobulina intravenosa para casos específicos. Este artículo hace una revisión de conceptos y pautas terapéuticas actuales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cacoub P, Mussette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. “The DRESS Syndrome: A Literature Review”. The Am J Med 2011; 124: 588-597.

  2. Criado PR, Avancini JM, Fachini R, Giuli C. “Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Drug-Induced Hypersensitivity Syndrome (DIHS): a review of current concepts”. An Bras Dermatol 2012; 87: 435-449.

  3. Fiszenson-Albala F, Auzerie V, Mahe E, et al. “A 6-month prospective survey of cutaneous drug reactions in a hospital setting”. Br J Dermatol 2003; 149: 1018-1022.

  4. Piñana E, Lei SH, Merino R, Melgosa M, De la Vega R, Gonzales-Obeso E, et al. “DRESS-Syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpesvirus 6 in a 11-year old Caucasian boy”. J Clin Pharm Ther 2010; 35: 365-370.

  5. Gentile I, Talamo M, Borgia G. “Is the drug-induced hypersensitivity syndrome (DIHS) due to herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review”. BMC Infectious Dis 2010; 10: 49.

  6. Kennebeck GA. “Anticonvulsant hypersensitivity Syndrome”. J Am Board Fam Pract 2000; 13: 364-370.

  7. Shiohara T, Inaoka M, Kano Y, “Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and anti-drug immune responses. Allergol Int 2006; 55: 1-8.

  8. Kardaun SH, Sidoroff A, Vallerye-Allanore L, et al. “Variability in the clinical patternf of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exists?” Br J Dermatol 2007: 156; 609-611.

  9. Natkunarajah J, Goolamali S, Craythorne E, et al. “Ten cases o drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulse intravenous methylprednisolone”. Eur J Dermatol 2011; 21: 385-391.

  10. Jeung YJ, Lee JY, Oh MJ, Chull D, Lee BJ. “Comparison of the Causes and Clinical Features of Drug Rash with Eosinophilia and Systemic Symptoms and Stevens-Johnson Syndrome”. Allergy, Asthma Immunol Res 2010; 2: 123-126.

  11. Mardivirin L, Valeyrie L, Branlant E, et al. “Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro”. Eur J Dermatol 2010; 20: 68-73.

  12. 12. Kawakami T, Fujita A, Takeuchi S, et al. “Drug-induced hypersensitivity syndrome: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease”. J Am Acad Dermatol 2009; 60: 146-149.

  13. 13. Um SJ, Lee SK, Kim YH, et al. “Clinical Features of Drug-Induced Hypersensitivity Syndrome in 38 Patients≠. J Investig Allergol Clin Immunol 2010; 20: 556-562.

  14. Phillips EJ, Chung WH, Mockenhaput M, et al. “Drug Hypersensitivity: Pharmacogenetics and Clinical Syndromes”. J Allergy Clin Immunol 2011; 127(3 Suppl):S60-S66.

  15. Estrella V, Baroni E, Leroux MB, Sánchez A, et al. “Síndrome de hipersensibilidad a anticonvulsivantes (SHA)”. Rev Argent Dermatol 2007; 88: 46-54.

  16. Magliano J, Álvarez M, Salmentón M. “Síndrome DRESS por carbamazepina”. Arch Pediatr Urug 2009; 80: 291-295.

  17. O’Meara P, Borici R, Morton R, Ellis AK. “DRESS with delayed onset acute interstitial nephritis and profound refractory eosinophilia secondary to Vancomycin”. Allergy Asthma Clin Immunology 2011; 7: 16.

  18. Tas S, Simonart T. “Management of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS Syndrome): An Update”. Dermatology 2003; 206: 353-356.

  19. Hassan S, Wtz R, Zouein E. “Alpurinol causing drug rash with eosinophilia and systemic symptoms syndrome: a challenging diagnosis”. International Journal General Medicine 2011; 4: 789-792.

  20. Sánchez X, Merlano C, Cruz CM. “Síndrome de hipersensibilida da medicamentos con eosinofilia y síntomas sistémicos (DRESS)”. Rev Asoc Col Dermatol 2008; 116: 208-210.

  21. Yoo H. “Hypersensitivity Syndrome with an epoxide hydrolse defect”. Br J Dermatol 1999; 140: 181-183.

  22. Carbona B, Moreno M, Díaz M. “Síndrome de hipersensibilidad a drogas”. Dermatología Argentina 2005; XI: 211.

  23. Ting T. “Anticonvulsant Hypersensitivity Syndrome: Identification and Management”. Curr Treat Options Neurol 2007; 9: 243-248.

  24. Santhamoorthy P, Alexander KJ, Alsubaili A. “Intravenous immunoglobulin in the treatment of drug rash eosinophilia and systemic symptoms caused by phenitoin”. Ann Indian Acad Neurol 2012; 15: 320-322.

  25. Camous X, Calbo S, Picard D, Musette P “Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis”. Curr Op Imm 2012; 24: 730-735.




2020     |     www.medigraphic.com